CN1563088B - 一种抗流行性感冒特异性复合IgY及其制剂 - Google Patents
一种抗流行性感冒特异性复合IgY及其制剂 Download PDFInfo
- Publication number
- CN1563088B CN1563088B CN 200410008799 CN200410008799A CN1563088B CN 1563088 B CN1563088 B CN 1563088B CN 200410008799 CN200410008799 CN 200410008799 CN 200410008799 A CN200410008799 A CN 200410008799A CN 1563088 B CN1563088 B CN 1563088B
- Authority
- CN
- China
- Prior art keywords
- influenza virus
- igy
- liquid
- virus
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010022000 influenza Diseases 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000002131 composite material Substances 0.000 title description 18
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 164
- 239000000427 antigen Substances 0.000 claims abstract description 63
- 102000036639 antigens Human genes 0.000 claims abstract description 63
- 108091007433 antigens Proteins 0.000 claims abstract description 63
- 239000007924 injection Substances 0.000 claims abstract description 31
- 238000002347 injection Methods 0.000 claims abstract description 31
- 239000003889 eye drop Substances 0.000 claims abstract description 5
- 229940012356 eye drops Drugs 0.000 claims abstract description 5
- 239000007922 nasal spray Substances 0.000 claims abstract description 5
- 229940097496 nasal spray Drugs 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 76
- 239000007788 liquid Substances 0.000 claims description 64
- 241000700605 Viruses Species 0.000 claims description 51
- 235000013601 eggs Nutrition 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- 238000003756 stirring Methods 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 29
- 238000005336 cracking Methods 0.000 claims description 27
- 230000036039 immunity Effects 0.000 claims description 27
- 239000006228 supernatant Substances 0.000 claims description 26
- 239000000287 crude extract Substances 0.000 claims description 22
- 239000012153 distilled water Substances 0.000 claims description 21
- 210000002969 egg yolk Anatomy 0.000 claims description 20
- 102000002322 Egg Proteins Human genes 0.000 claims description 19
- 108010000912 Egg Proteins Proteins 0.000 claims description 19
- 238000004440 column chromatography Methods 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 210000001643 allantois Anatomy 0.000 claims description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 15
- 239000002953 phosphate buffered saline Substances 0.000 claims description 15
- 241000287828 Gallus gallus Species 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 13
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 12
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 12
- 210000003837 chick embryo Anatomy 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 12
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 12
- 229940031418 trivalent vaccine Drugs 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 238000012546 transfer Methods 0.000 claims description 10
- 230000003612 virological effect Effects 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 238000005227 gel permeation chromatography Methods 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 229960005486 vaccine Drugs 0.000 claims description 9
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 8
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 8
- 210000003278 egg shell Anatomy 0.000 claims description 8
- 210000000969 egg white Anatomy 0.000 claims description 8
- 235000014103 egg white Nutrition 0.000 claims description 8
- 238000005374 membrane filtration Methods 0.000 claims description 8
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 8
- 238000000197 pyrolysis Methods 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 8
- 235000010413 sodium alginate Nutrition 0.000 claims description 8
- 239000000661 sodium alginate Substances 0.000 claims description 8
- 229940005550 sodium alginate Drugs 0.000 claims description 8
- 238000000108 ultra-filtration Methods 0.000 claims description 8
- 210000003743 erythrocyte Anatomy 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 238000005507 spraying Methods 0.000 claims description 7
- 210000001136 chorion Anatomy 0.000 claims description 6
- 230000000249 desinfective effect Effects 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 239000006166 lysate Substances 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 5
- 238000013019 agitation Methods 0.000 claims description 5
- 238000002298 density-gradient ultracentrifugation Methods 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 238000001641 gel filtration chromatography Methods 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 5
- 238000002649 immunization Methods 0.000 claims description 5
- 239000003456 ion exchange resin Substances 0.000 claims description 5
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000007923 nasal drop Substances 0.000 claims description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 239000003380 propellant Substances 0.000 claims description 4
- 239000008227 sterile water for injection Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000010009 beating Methods 0.000 claims description 3
- 230000023555 blood coagulation Effects 0.000 claims description 3
- 239000006189 buccal tablet Substances 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 235000013345 egg yolk Nutrition 0.000 claims description 3
- 238000005342 ion exchange Methods 0.000 claims description 3
- 229940057995 liquid paraffin Drugs 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 239000008176 lyophilized powder Substances 0.000 claims description 3
- 210000000071 ovigerm Anatomy 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 210000000998 shell membrane Anatomy 0.000 claims description 3
- 229960001005 tuberculin Drugs 0.000 claims description 3
- 239000008215 water for injection Substances 0.000 claims description 3
- 238000012371 Aseptic Filling Methods 0.000 claims description 2
- 229920005654 Sephadex Polymers 0.000 claims description 2
- 239000012507 Sephadex™ Substances 0.000 claims description 2
- 229940046011 buccal tablet Drugs 0.000 claims description 2
- 239000003610 charcoal Substances 0.000 claims description 2
- 238000005262 decarbonization Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000011146 sterile filtration Methods 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 48
- 208000003322 Coinfection Diseases 0.000 abstract description 46
- 239000007921 spray Substances 0.000 abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 9
- 229920001184 polypeptide Polymers 0.000 abstract description 8
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 229960003971 influenza vaccine Drugs 0.000 abstract description 6
- 230000009471 action Effects 0.000 abstract description 3
- 229940100662 nasal drops Drugs 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 21
- 241000272534 Struthio camelus Species 0.000 description 19
- 241000272814 Anser sp. Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000004044 response Effects 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 7
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 6
- 241000272525 Anas platyrhynchos Species 0.000 description 6
- 241000606768 Haemophilus influenzae Species 0.000 description 6
- 108010001160 IgY Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 229960004873 levomenthol Drugs 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 239000000185 hemagglutinin Substances 0.000 description 5
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 102000005348 Neuraminidase Human genes 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 239000012506 Sephacryl® Substances 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 101710117545 C protein Proteins 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 2
- 229960003752 oseltamivir Drugs 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229960000888 rimantadine Drugs 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 229960001028 zanamivir Drugs 0.000 description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 2
- 241000272808 Anser Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000204003 Mycoplasmatales Species 0.000 description 1
- 229940123424 Neuraminidase inhibitor Drugs 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011100 viral filtration Methods 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410008799 CN1563088B (zh) | 2004-03-19 | 2004-03-19 | 一种抗流行性感冒特异性复合IgY及其制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410008799 CN1563088B (zh) | 2004-03-19 | 2004-03-19 | 一种抗流行性感冒特异性复合IgY及其制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1563088A CN1563088A (zh) | 2005-01-12 |
CN1563088B true CN1563088B (zh) | 2010-10-13 |
Family
ID=34477732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410008799 Expired - Lifetime CN1563088B (zh) | 2004-03-19 | 2004-03-19 | 一种抗流行性感冒特异性复合IgY及其制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1563088B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1958608B (zh) * | 2005-10-31 | 2012-07-04 | 深圳雅臣生物科技有限公司 | 抗禽流感特异性IgY的制备方法及其制剂 |
CN102406930A (zh) * | 2011-11-25 | 2012-04-11 | 成都康华生物制品有限公司 | 季节性流感病毒裂解疫苗的制备方法 |
CN105727287A (zh) * | 2014-12-06 | 2016-07-06 | 郑长义 | 一种含复合亚型免疫抗体的禽流感免疫鸡蛋生产制程方法 |
CN104546715B (zh) * | 2014-12-22 | 2018-01-16 | 蓝佳堂生物医药(福建)有限公司 | 一种用于上呼吸道感染的复合抗体口腔喷剂及其制备方法 |
CN106860862A (zh) * | 2017-01-18 | 2017-06-20 | 江苏安泰生物技术有限公司 | 一种抗感染性疾病的组合物和雾化喷剂及其制备方法 |
CN113429480A (zh) * | 2021-08-26 | 2021-09-24 | 深圳市雅臣智能生物工程有限公司 | 广谱抗冠状病毒和流感病毒及口腔致病菌复合IgY及其制剂 |
-
2004
- 2004-03-19 CN CN 200410008799 patent/CN1563088B/zh not_active Expired - Lifetime
Non-Patent Citations (4)
Title |
---|
Kostolansky-F等.antibody response to hidden epitope of influenzaAhaemagglutinin elicited by anti-idiotypic antibodies.Acta Virologica38 4.1994,215页摘要. |
Kostolansky-F等.antibody response to hidden epitope of influenzaAhaemagglutinin elicited by anti-idiotypic antibodies.Acta Virologica38 4.1994,215页摘要. * |
张雪梅等.抗甲3型流感病毒卵黄抗体的研制.微生物学免疫学进展30 3.2002,30(3),17页正文左栏第二段至第19页左栏最后一段. |
张雪梅等.抗甲3型流感病毒卵黄抗体的研制.微生物学免疫学进展30 3.2002,30(3),17页正文左栏第二段至第19页左栏最后一段. * |
Also Published As
Publication number | Publication date |
---|---|
CN1563088A (zh) | 2005-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1958608B (zh) | 抗禽流感特异性IgY的制备方法及其制剂 | |
Taylor et al. | Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. | |
Bean et al. | Biologic potential of amantadine-resistant influenza A virus in an avian model | |
CN104602709B (zh) | 新型ha结合试剂 | |
CN105934441A (zh) | 新型sars免疫原性组合物 | |
CN101516395A (zh) | 抗屈曲病毒感染的疫苗 | |
CN113999321B (zh) | 一种具有广谱中和活性的新冠病毒抗体及其制备方法与应用 | |
CN113087791B (zh) | 广谱抗变异新冠病毒IgY和复合抗体及制备方法和组合制剂 | |
WO2021155639A1 (zh) | 抗SARS-CoV-2和其它冠状病毒IgY及其小分子抗体以及应用 | |
CN116350769B (zh) | 一种新冠病毒和流感病毒的联合疫苗、其制备方法与应用 | |
CN102397559B (zh) | 广谱型流感疫苗及其制备方法 | |
CN1563088B (zh) | 一种抗流行性感冒特异性复合IgY及其制剂 | |
Zeigler et al. | Epitope-targeting platform for broadly protective influenza vaccines | |
CN101450208B (zh) | 喷鼻免疫流感多价疫苗的制备及其方法 | |
CN104844708A (zh) | 马抗H7N9亚型流感特异免疫球蛋白F(ab’)2及其制备方法 | |
CA2716340A1 (en) | Immunogenic influenza composition | |
CN105535954A (zh) | 一种用于防治流感、禽流感、上呼吸道感染的疫苗 | |
US20100196495A1 (en) | Delivery of flu antibodies to surfaces in contact with air | |
CN101885757A (zh) | 禽流感病毒血凝素、表位肽和抗它们的单克隆抗体及其应用 | |
CN101555281A (zh) | 抗甲型H1N1流感病毒特异性IgY的制备方法及其相关制剂 | |
CN103789272B (zh) | H9亚型禽流感病毒分离株以及由其制得的疫苗组合物 | |
CN113248575B (zh) | 一种针对SARS-CoV-2的重组蛋白疫苗及其制备方法 | |
CN109563138A (zh) | 经改造的流感血凝素多肽的修饰 | |
CN101947317A (zh) | 一种h5n1禽流感病毒样颗粒疫苗的规模化制备方法 | |
CN100413536C (zh) | 人用狂犬病裂解疫苗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN YA-CHEN BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: YA CHEN PHARMACEUTICAL GROUP (FAR EAST) LTD. Effective date: 20080606 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080606 Address after: A biological incubation building, high tech Development Zone, Middle District, Nanshan District hi tech Zone, Guangdong, Shenzhen 1-204, China: 518057 Applicant after: Shenzhen Yachen Biological Technology Co.,Ltd. Address before: Room 768, building three, Bagua Road, Futian District, Guangdong, Shenzhen Province, China: 518000 Applicant before: Jason Medical Group (Far East) Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160224 Address after: 518057 room 1211, Longgang Internet industry training center, Bantian street, Guangdong Road, Longgang District, Shenzhen, China Patentee after: SHENZHEN YACHEN AIJI BIOENGINEERING Co.,Ltd. Address before: 518057 a biological incubation building in central high tech Zone, Nanshan District hi tech Zone, Guangdong, Shenzhen 1-204 Patentee before: Shenzhen Yachen Biological Technology Co.,Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: SHENZHEN YACHEN AIJI BIOENGINEERING Co.,Ltd. Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice | ||
CP03 | Change of name, title or address |
Address after: 518057 C, 401, Baoshan Road 16, Baoshan Road, Pingshan street, Pingshan District, Shenzhen, Guangdong, China, 401 Patentee after: SHENZHEN JASON INTELLIGENT BIOTECHNOLOGY COMPANY LIMLTED. PRC Address before: 518057 Guangdong Shenzhen Longgang District Bantian Street North Ring Road Longgang Internet industry incubator room 1211 Patentee before: SHENZHEN YACHEN AIJI BIOENGINEERING Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20101013 |